Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, affecting nearly one-third of the global population 1 . Lifestyle modification, including nutritional intervention, remains the cornerstone of MASLD management. Although weight loss of >7-10% is recommended to improve liver histology and metabolic outcomes, individual responses to dietary interventions vary considerably, reflecting the heterogeneous clinical, metabolic, and biological characteristics of the disease.Precision nutrition has emerged as a promising framework to address this heterogeneity by integrating lifestyle and behavioral factors, body composition, metabolic biomarkers, environmental exposures, cultural preferences, and genomic, molecular, and microbiome-related characteristics into individualized nutritional approaches 2 . As illustrated in Figure 1, precision nutrition in MASLD encompasses a continuum from multidimensional patient characterization and integrated patient assessment to the implementation of personalized dietary and lifestyle interventions aimed at improving both hepatic and extrahepatic outcomes.The articles assembled in this Research Topic illustrate how the principles of precision nutrition can be translated into practical strategies for the management of MASLD.The marked heterogeneity partly explains why uniform nutritional recommendations often produce variable responses in MASLD. Integrated patient assessment provides a framework to identify clinically meaningful sources of heterogeneity that may influence disease progression and response to dietary interventions. Metabolic and inflammatory phenotyping are key components of this multidimensional assessment. In this context, Ntikoudi emphasizes that clinically meaningful metabolic and inflammatory profiles can be identified using readily available biomarkers, such as HOMA-IR, TG/HDL-C, and hs-CRP, without necessarily relying on complex omics technologies.Along similar lines, Priego-Parra et al. 3 highlighted the triglyceride-glucose-waist circumference (TyG-WC) index as a practical surrogate of insulin resistance, visceral adiposity, and cardiometabolic risk, illustrating how accessible metabolic biomarkers can guide personalized nutritional management in MASLD. These advances reinforce the growing role of simple metabolic and nutritional biomarkers in refining patient assessment and guiding precision nutrition.Accessible metabolic and nutritional biomarkers are emerging as key tools for refining integrated patient assessment and improving risk stratification in MASLD. In Beyond its role as a relevant therapeutic intervention, diet has been recognized as a significant contributor to the development of MASLD and a major modifiable risk factor. In this context, Qiu et al. showed that greater to the Planetary Health Diet Index (PHDI) was associated with a lower likelihood of MASLD, with the effect partly mediated by body mass index and waist circumference. In addition, Yang et al. demonstrated that greater adherence to the MIND Diet Score was associated with improved hepatic and metabolic health together with a more favorable gut microbiota profile, supporting the potential role of comprehensive dietary quality indices in precision nutrition. Siani et al. further reported an inverse, dose-dependent association between Italian-style coffee consumption and MASLD risk, with lower odds observed as daily coffee intake increased. Although this observational study does not establish causality, it highlights the potential relevance of specific dietary exposures in modulating MASLD risk. Taken together, these studies reinforce the importance of dietary quality and selected nutritional exposures in MASLD and support the inclusion of both overall dietary patterns and individual dietary components in nutritional assessment.Dietary interventions, reduced intake of sugar-sweetened beverages (Li et al), and regular physical activity improve metabolic health and body composition while modulating key pathways involved in disease progression, including insulin resistance, systemic inflammation, and gut microbial ecology. Growing evidence positions the gut microbiota as a key mediator linking environmental exposures with hepatic and metabolic dysfunction. Within this framework, diet should be considered not only as a source of nutrients but also as a therapeutic modulator of hostmicrobiome interactions. Bioactive components, including omega-3 fatty acids, coffee, tea, and fermented foods, have been associated with favorable metabolic and microbial profiles, although their molecular mechanisms remain incompletely understood.These effects are closely related to the gut-liver axis, through which microbial metabolites and microbial-associated molecular patterns influence hepatic homeostasis. During dysbiosis, increased exposure to lipopolysaccharides, altered bile acid metabolism, and other microbial products may promote adipose tissue dysfunction, oxidative stress, mitochondrial impairment, and chronic inflammation, thereby supporting dietary and microbiota-targeted approaches as therapeutic Collectively, these advances support a shift from a liver-centered view of MASLD toward a systems-based framework integrating host metabolism, immunity, and the intestinal microbiome. This perspective aligns with the concept of the human holobiont and may facilitate the development of more precise and biologically informed therapeutic strategies.Lifestyle modification remains the cornerstone of MASLD management, with dietary intervention and increased physical activity representing the foundation of current therapeutic strategies. However, substantial interindividual variability in treatment response highlights the limitations of a uniform approach. Integrating precision nutrition into clinical care offers an opportunity to tailor dietary interventions according to each patient's metabolic phenotype, body...